UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
June 7, 2004
Date of Report (Date of earliest event reported)
NEORX CORPORATION
(Exact Name of Registrant as Specified in Charter)
Washington |
| 0-16614 |
| 91-1261311 |
(State or Other Jurisdiction |
| (Commission File No.) |
| (IRS Employer |
|
|
|
|
|
300 Elliott Avenue West, Suite 500, Seattle, Washington |
| 98119-4114 | ||
(Address of principal executive offices) |
| (Zip Code) | ||
| ||||
(206) 281-7001 | ||||
(Registrant’s telephone number, including area code) | ||||
Item 5. Other Events
NeoRx presented data from its phase II dosimetry study of STR™ (Skeletal Targeted Radiotherapy) in patients with multiple myeloma at the 2004 Annual Meeting of the American Society of Clinical Oncology (ASCO). The data demonstrated positive trends in both patient response and safety. See press release dated June 7, 2004 attached to this report as Exhibit 99.1 and incorporated herein by reference.
Item 7. Financial Statements and Exhibits
(c) Exhibits
Exhibit |
| Description |
|
|
|
99.1 |
| Press release dated June 7, 2004 |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEORX CORPORATION | ||
| (Registrant) | ||
|
| ||
Date: June 10, 2004 | By: | /s/ MICHAEL K. JACKSON |
|
| Michael K. Jackson | ||
| Corporate Controller and Chief Accounting Officer | ||
2
EXHIBIT INDEX
Exhibit No. |
| Description |
|
|
|
99.1 |
| Press release dated June 7, 2004 |
3
